Search

Your search keyword '"Seyyed Mohammad Ghaffari"' showing total 3 results
Start Over Author "Seyyed Mohammad Ghaffari"
3 results on '"Seyyed Mohammad Ghaffari"'

1. Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial

Author

Somaieh Ashrafi, Seyyed Mohammad Ghaffari, Hatam Boostani, Somaieh Raz, Negar Ebadi, Zahra Ashrafi, and Pedram Nazari

Subjects
schizophrenia, negative symptoms, simvastatin, Specialties of internal medicine, RC581-951, Infectious and parasitic diseases, RC109-216
Abstract

Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial effects in schizophrenia regarding their prominent anti-inflammatory properties. Objectives: This study was designed to evaluate the effects of simvastatin on schizophrenia symptoms. Patients and Methods: In a double-blinded randomized clinical trial, 40 hospitalized schizophrenia patients (according to the DSM-IV-TR criteria) were studied for 6 weeks. One group of the patients (n=20) received simvastatin (with the dose of 40 mg/d) and the other group received (n=20) placebo. The patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia symptoms. Data were analyzed with mixed model repeated measure ANOVA, t test, and χ2 test or Fischer’s exact test by SPSS software. The significant cutoff was considered at P

Published
2022
Full Text
View/download PDF

2. EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)

Author

Seyyed Mohammad Ghaffari, Abedin Hoseini, Mehdi Sayyah, Mohammad Sayyah, and Hatam Boostani

Subjects
medicine.medical_specialty, medicine.medical_treatment, Placebo, behavioral disciplines and activities, humanities, law.invention, Clinical trial, Psychiatry and Mental health, Clinical Psychology, Pharmacotherapy, Sexual dysfunction, Randomized controlled trial, law, Internal medicine, mental disorders, medicine, Aripiprazole, medicine.symptom, Antipsychotic, Prospective cohort study, Psychiatry, Psychology, medicine.drug
Abstract

Background Obsessive-compulsive disorder (OCD) is a chronic disorder with unknown etiology. Failure in OCD treatmentcompulsive is common and finding effective augmentations in treatment of OCD will benefit patients. Antipsychotic augmentation is a common strategy for treatment resistant OCD. This trial evaluated the efficacy of adding aripiprazole in patients whose OCD was insufficiently responsive to an adequate SSRI treatment. Methods Thirty-nine adult outpatients, who met the DSM-IV-TR criteria for OCD and had treatment resistant OCD were evaluated in a double-blind randomized clinical trial. The patients received either aripiprazole 10 mg/day or placebo, for 12 weeks. Data were analyzed using intention-to-treat analysis with last observation carried forward. All statistical tests were two-sided, and were considered statistically significant at P < 0.05. Results A significant reduction in total scores of Y-BOCS (P < 0.0001) was found in the aripiprazole group. Aripiprazole was generally well tolerated. There was no significant difference between the two groups in terms of observed side effects. Conclusion Results of the present study indicate that aripiprazole could be an effective augmentation medicine in treatment resistant OCD.

Published
2012
Full Text
View/download PDF

3. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)

Author

Mehdi, Sayyah, Mohammad, Sayyah, Hatam, Boostani, Seyyed Mohammad, Ghaffari, and Abedin, Hoseini

Subjects
Adult, Male, Psychiatric Status Rating Scales, Obsessive-Compulsive Disorder, Aripiprazole, Quinolones, Piperazines, Treatment Outcome, Double-Blind Method, Humans, Drug Therapy, Combination, Female, Prospective Studies, Selective Serotonin Reuptake Inhibitors, Antipsychotic Agents
Abstract

Obsessive-compulsive disorder (OCD) is a chronic disorder with unknown etiology. Failure in OCD treatmentcompulsive is common and finding effective augmentations in treatment of OCD will benefit patients. Antipsychotic augmentation is a common strategy for treatment resistant OCD. This trial evaluated the efficacy of adding aripiprazole in patients whose OCD was insufficiently responsive to an adequate SSRI treatment.Thirty-nine adult outpatients, who met the DSM-IV-TR criteria for OCD and had treatment resistant OCD were evaluated in a double-blind randomized clinical trial. The patients received either aripiprazole 10 mg/day or placebo, for 12 weeks. Data were analyzed using intention-to-treat analysis with last observation carried forward. All statistical tests were two-sided, and were considered statistically significant at P0.05.A significant reduction in total scores of Y-BOCS (P0.0001) was found in the aripiprazole group. Aripiprazole was generally well tolerated. There was no significant difference between the two groups in terms of observed side effects.Results of the present study indicate that aripiprazole could be an effective augmentation medicine in treatment resistant OCD.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results